UMI-77

CAS No. 518303-20-3

UMI-77 ( UMI-77, UMI77, UMI 77 )

Catalog No. M14810 CAS No. 518303-20-3

A potent and selective Mcl-1 inhibitor with Ki of 0.49 uM; displays >10 fold selectivity against Bcl-w, Bfl-1, Bcl-xL and Bcl-2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 146 In Stock
5MG 172 In Stock
10MG 310 In Stock
25MG 600 In Stock
50MG 832 In Stock
100MG 1165 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    UMI-77
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent and selective Mcl-1 inhibitor with Ki of 0.49 uM; displays >10 fold selectivity against Bcl-w, Bfl-1, Bcl-xL and Bcl-2.
  • Description
    A potent and selective Mcl-1 inhibitor with Ki of 0.49 uM; displays >10 fold selectivity against Bcl-w, Bfl-1, Bcl-xL and Bcl-2; inhibits cell growth and induces apoptosis in pancreatic cancer cells; blocks the heterodimerization of Mcl-1/Bax and Mcl-1/Bak in cells; inhibits tumor growth in BxPC-3 xenograft model.
  • Synonyms
    UMI-77, UMI77, UMI 77
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    Mcl-1
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    518303-20-3
  • Formula Weight
    468.34
  • Molecular Formula
    C18H14BrNO5S2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 28 mg/mL
  • SMILES
    C1=CC=C2C(=C1)C(=CC(=C2O)SCC(=O)O)NS(=O)(=O)C3=CC=C(C=C3)Br
  • Chemical Name
    Acetic acid, 2-[[4-[[(4-bromophenyl)sulfonyl]amino]-1-hydroxy-2-naphthalenyl]thio]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Abulwerdi F, et al. Mol Cancer Ther. 2014 Mar;13(3):565-75.
2. Mohammad RM, et al. Semin Cancer Biol. 2015 Dec;35 Suppl:S78-103.
3. Korfi K, et al. Cell Death Dis. 2016 Apr 7;7:e2177.
molnova catalog
related products
  • Maritoclax

    Maritoclax (Marinopyrrole A) is a novel and specific Mcl-1 inhibitor.

  • Lisaftoclax

    Bcl-2/Bcl-xl inhibitor 1 is a dual Bcl-2 and Bcl-xl inhibitor (IC50s: 2 nM and 5.9 nM for Bcl-2 and Bcl-xl) with anti-tumor activity. It is extracted from patent WO2018027097A1.

  • BI-3812

    A highly potent and efficacious BCL6 inhibitor that potently inhibits the interaction of the BTB/POZ domain of BCL6 with several co-repressors in vitro with IC50 of <3 nM.